A Phase I Dose Escalating Study of Bortezomib and Lenalidomide in Patients With Untreated or Previously Treated, Primary and Secondary Non 5q- Del Myelodysplasia.
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2012
At a glance
- Drugs Bortezomib; Lenalidomide
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Biomarker
- 07 Mar 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.